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7SHORT REPORT Open AccessPreoperative Glucagon-like peptide-1 receptor
imaging reduces surgical trauma and pancreatic
tissue loss in insulinoma patients: a report of
three cases
Anna Silvia Wenning1, Paul Kirchner2, Kwadwo Antwi3, Melpomeni Fani3, Damian Wild3, Emanuel Christ2
and Beat Gloor1*Abstract
Background: Insulinomas are rare tumors, in the majority of cases best treated by surgical resection. Preoperative
localization of insulinoma is challenging. The more precise the preoperative localization the less invasive and safer is
the resection. The purpose of the study is to check the impact of a new technique to localize insulinoma on the
surgical strategy.
Findings: We present exact preoperative localization with Glucagon-like peptide-1 receptor (GLP-1R) imaging. This
allows a more precise resection thereby reducing surgical access trauma, loss of healthy pancreatic tissue and
increasing safety and quality of the surgical intervention.
Conclusion: With the help of precise preoperative localization of insulinoma with GLP-1R imaging the surgeon is
able to minimize the amount of resected healthy pancreatic tissue. We hypothesize that GLP-1R imaging will
become a preoperative diagnostic tool to be used for many patients scheduled for open or laparoscopic insulinoma
resection.Introduction
Precise preoperative localization of insulinoma is chal-
lenging. In 90% insulinomas are located in the pancreas,
most of them with a size below 2 cm. In a recent sys-
tematic review computed tomography (CT) is described
as diagnostic modality of choice and reaches a rate of
correct localization of 44.4% [1]. Magnetic resonance
imaging (MRI) is an accepted alternative with a rate of
correct localization of 47.4%. The sensitivity showed a
wide variation between 2–95.3% for CT (mean 43.9%)
and 0-100% for MRI (mean 53.3). With intraoperative
ultrasound insulinomas of a size of 2-3 mm can be de-
tected [2]. The rate of correct localization was reviewed
as 91.5% with a mean sensitivity of 91.2%. Therefore,
open (or laparoscopic) surgical exploration combined
with intraoperative ultrasound remains the preferred* Correspondence: Beat.Gloor@insel.ch
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unless otherwise stated.approach to localize insulinoma. Unfortunately, with this
technique the entire pancreas needs to be surgically ex-
posed if the preoperative CT and or MRI do not exactly
show the localization of the insulinoma.
Glucagon-like peptide-1 receptor (GLP-1R) imaging
using 111In-exendin-4 SPECT/CT has been shown to be
more sensitive in detection of insulinoma than CT or
MRI [3-5]. Until now, only case series have been pub-
lished. In detail, in 2008 6 patients had a 100% correct
preoperative localization rate. The following prospective
multicenter study showed a sensitivity of 95% for the
GLP-1R imaging in contrast to 47% for CT or MRI. Es-
pecially in patients without pathological findings in rou-
tine diagnostic GLP-1R imaging was helpful to localize
insulinoma. However it is important to know that many
malign insulinomas lack GLP-1R and will not be detect-
able by GLP-1R targeted imaging.
We hypothesize that exact preoperative localization
with GLP-1R imaging allows for a more precise resec-
tion thereby reducing surgical access trauma, loss ofal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 a) and b) MRI without pathological finding in the pancreatic corpus whereas 111In-DOTA-exndin-4 SPECT/CT detects the insulinoma. c)
Enucleation was performed and d) the pancreatic capsule was closed by direct suture. e) The insulinoma (14 mm) was surrounded by a minimal
mass of healthy tissue.
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ity of the surgical intervention.
Methods
We present three consecutive cases of insulinomas
which are not included in previously published series
and focus on surgical tactics and safety. Prior to surgery,
all patients underwent GLP-1R imaging using 111In-
DOTA-exendin-4 SPECT/CT in addition to CT or MRI.
Synthesis and labelling of 111In-DOTA-exendin-4 was
published elsewhere [4]. SPECT/CT of the abdomen wasFigure 2 a) 111In-DOTA-exendin-4 SPECT/CT localized the insulinoma b
confirmed this localization behind the superior mesenteric vein and c)
uncinate process).performed at 4 and 72 hours after i.v. injection of 111In-
DOTA-exendin-4. Surgery was done by one single surgi-
cal team (ASW and BG).
Results
In the first patient, MRI showed a small hypervascular
lesion in the uncinate process and a normal pancreatic
corpus. In contrast GLP-1R imaging using 111In-DOTA-
exendin-4 SPECT/CT detected an insulinoma in the pan-
creatic corpus (Figure 1a and b). Surgical exploration was
performed with an open access. Intraoperative inspectionetween superior mesenteric artery and vein. b) Open exploration
the tumor was enucleated. (*: superior mesenteric vein, #:
Figure 3 a) A large insulinoma of the pancreatic tail was detected with 111In-DOTA-exendin-4 SPECT/CT and b) resected laparoscopically
(pancreatic tail resection).
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enucleated (Figure 1c,d and e). Histology showed a
14 mm insulinoma. No further lesions were found in
the uncinate process.
MRI of the second patient showed no pathologies of
the pancreas. Only GLP-1R imaging detected a lesion
dorsal of the uncinate process in projection of the
interspace between superior mesenteric vein and ar-
tery (Figure 2a). The open approach focused on prep-
aration of the uncinate process and the superior
mesenteric vein. Enucleation of a small tumor was
performed without complications (Figure 2b and c)
and confirmed histologically.
The third patient underwent CT and MRI. Both mo-
dalities did not detect the insulinoma of 1.6 cm in the
pancreatic tail, that became visible in GLP-1R imaging
(Figure 3a). Pancreatic tail resection was performed
laparoscopically. The tumor was sent to frozen section
and verified (Figure 3b) allowing for omission of ex-
posure of the body and head of the pancreas.
None of the three patients developed postoperative
complications (especially no pancreatic fistula and no
diabetes mellitus). No persisting hypoglycemia oc-
curred. A summary of results of the diagnostic test
and intraoperative findings is given in Table 1.Table 1 Preoperative imaging to localize insulinoma, intraope
Imaging/surgical procedure Patient 1 (f)
CT scan -
MRI Hypervascular lesion in
uncinate process
111In-DOTA-exendin-4
SPECT/CT
Pancreatic corpus
Intra-operative Pancreatic corpus
Access Open
Technique EnucleationDiscussion
In all three patients GLP-1R imaging was crucial for plan-
ning the resection. Operation was performed pointing
straight to the localization of interest. The access was kept
as minimal as possible und healthy pancreatic tissue was
preserved.
In the first patient preoperative imaging did not show
the neuroendocrine tumor but falsely found a lesion in
the uncinate process. With the help of the GLP-1R im-
aging we were able to keep surgical exploration of the
uncinate process at a minimum.
In the third patient GLP-1R imaging led to laparo-
scopic resection. Laparoscopic sonography is an estab-
lished method, but digital palpation cannot be used.
Therefore only a reliable preoperative localization of
insulinoma allows a safe and fast laparoscopic approach.
Based on these three cases and the previously published
data we recommend preoperative GLP-1R imaging in insu-
linoma patients. Especially in ectopic or small lesions below
a size of 1 cm and in MEN1 patients who sometimes suffer
from multiple insulinomas or if preoperative imaging does
not at all or not correctly show the lesion the benefit for
our patients is high. Another advantage is the possibility to
use the gamma-probe to detect an insulinoma intraopera-
tively, as long as the resection is planned less than 14 daysrative finding and surgical approach in three patients
Patient 2 (f) Patient 3 (m)
- Normal
Normal Normal
Dorsal of uncinate
process
Pancreatic tail
Dorsal of uncinate
process
Pancreatic tail
Open Laparoscopic
Enucleation Pancreatic tail
resection
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cessful operation is reduced to a minimum.
In our experience the preoperative GLP-1R imaging leads
to focused access to the insulinoma, preservation of more
normal pancreatic tissue and thus to a higher precision and
safety of the procedure.
Conclusion
In our view preoperative GLP-1R imaging is important
for planning surgical treatment in insulinoma. For the
future it may allow to perform laparoscopic resections
more frequently.
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